摘要
AMP激活的蛋白激酶(AMPK)作为信号,是在所有真核生物中控制细胞能量平衡的重要传感器。AMPK还参与脂肪酸氧化,葡萄糖转运,抗氧化,线粒体生物合成和炎症过程的调制。细胞生理和病理状态的AMPK的众多角色在前几年出版物的数量显著增加,在2014年里,有近1500篇科学论文讨论了此激酶。由于其在维持能量平衡的作用,AMPK信号通路功能障碍可能会导致在系统层面和许多疾病发展中的变化。其中,超过7000的鲜为人知的罕见疾病,特别是社会科学关联的事物,因为他们通常是慢性衰弱甚至危及生命并缺乏有效、安全的治疗方法。几位作者已经证实AMPK改变和调节在这些低流行疾病药物治疗的AMPK活性的有益效果。这些罕见的疾病,AMPK可以发挥重要的病理作用是线粒体病、肌营养不良、心血管疾病、神经退行性疾病,甚至某些类型的癌症,为AMPK作为抑制细胞增殖的作用。本文对AMPK和未来途径的病理生理作用的现有知识作为治疗罕见疾病的靶向。
关键词: AMPK,罕见疾病,线粒体疾病,肌营养不良症,共济失调毛细血管扩张、Peutz-Jeghers综合征,沃尔夫帕金森白色综合征,AMPK基因突变。
图形摘要
Current Drug Targets
Title:AMPK As A Target in Rare Diseases
Volume: 17 Issue: 8
Author(s): David Cotán, Marina Villanueva Paz, Elizabet Alcocer-Gómez, Juan Garrido-Maraver, Manuel Oropesa-Ávila, Mario de la Mata and Ana Delgado Pavón, Isabel de Lavera, Fernando Galán, Patricia Ybot-González, José A. Sánchez-Alcázar
Affiliation:
关键词: AMPK,罕见疾病,线粒体疾病,肌营养不良症,共济失调毛细血管扩张、Peutz-Jeghers综合征,沃尔夫帕金森白色综合征,AMPK基因突变。
摘要: The AMP-activated protein kinase (AMPK) has emerged as an important sensor of signals that control cellular energy balance in all eukaryotes. AMPK is also involved in fatty acid oxidation, glucose transport, antioxidant defense, mitochondrial biogenesis and the modulation of inflammatory processes. The numerous roles of AMPK in cell physiological and pathological states justified the notable increase in the number of publications in previous years, with almost 1500 scientific articles relative to this kinase in 2014. Due to its role in maintaining energy balance, a dysfunction in AMPK signalling pathway may result in perturbations at the systemic level that contribute to the development of many disease conditions. Among them, more than 7000 poorly-known rare diseases are particularly of social and scientific interest because they are usually chronically debilitating or even lifethreatening and lack effective and safe treatment. Several authors have demonstrated AMPK alterations and the beneficial effect of treatments with drugs regulating AMPK activity in some of these low prevalence pathologies. Among these rare diseases in which AMPK can play an important pathological role are mitochondrial disorders, muscular dystrophies, cardiovascular diseases, neurodegenerative pathologies, or even some types of cancer for the importance of AMPK as a suppressor of cell proliferation. This review focuses on current knowledge about the pathophysiological roles of AMPK and future approaches as therapeutic targeting in rare diseases.
Export Options
About this article
Cite this article as:
David Cotán, Marina Villanueva Paz, Elizabet Alcocer-Gómez, Juan Garrido-Maraver, Manuel Oropesa-Ávila, Mario de la Mata and Ana Delgado Pavón, Isabel de Lavera, Fernando Galán, Patricia Ybot-González, José A. Sánchez-Alcázar , AMPK As A Target in Rare Diseases, Current Drug Targets 2016; 17 (8) . https://dx.doi.org/10.2174/1389450117666160112110204
DOI https://dx.doi.org/10.2174/1389450117666160112110204 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Getting to the Heart of the Matter: Exploring Opportunities for Gene Therapy Treatment of Dystrophic Cardiomyopathy
Current Gene Therapy An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Application of Ghrelin
Current Pharmaceutical Design Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Mini-Reviews in Medicinal Chemistry Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Structural and Electrical Remodeling: From Myocardial Cytology to Cardiodiabetology
Current Vascular Pharmacology Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Current Medicinal Chemistry Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Meet Our Editorial Board Member
Current Drug Targets Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Current Pharmaceutical Design Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine The Evolving Therapy of Rheumatic Diseases, The Future is Now
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity
Current Cancer Drug Targets Chemo-drug Controlled-release Strategies of Nanocarrier in the Development of Cancer Therapeutics
Current Medicinal Chemistry